Japan’s Aging Problem Will Limit Industry Growth
Executive Summary
Japanese pharma growth is set to decelerate between 2016 and 2026 as an aging population and government pressure on drug prices will temper company revenues. PharmaVitae has analyzed eight leading public pharmaceutical companies in Japan to give a snapshot of the wider industry in the region.